Ignite Creation Date:
2025-12-25 @ 3:57 AM
Ignite Modification Date:
2026-04-13 @ 3:54 PM
Study NCT ID:
NCT06106802
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-10-30
First Post:
2023-10-12
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Sponsor:
Samsung Medical Center
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
2023-10-053
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None